Trials / Completed
CompletedNCT00219726
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase in Relapse After Allogeneic Stem Cell Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase who are in relapse after stem cell transplantation.
Detailed description
Patients will received Imatinib at a dose of 400mg daily. The tolerability of Imatinib given at a daily dose of 400mg will be assessed. The hematologic, cytogenetic and molecular responses will be evaluated at various check points. Donor/recipient chimerism during Imatinib therapy will be assessed. Survival will be estimated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib mesylate |
Timeline
- Start date
- 2002-05-01
- Completion
- 2007-07-01
- First posted
- 2005-09-22
- Last updated
- 2012-08-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00219726. Inclusion in this directory is not an endorsement.